179 related articles for article (PubMed ID: 3926590)
1. Systemic sclerosis (scleroderma) and esophageal adenocarcinoma: Is increased patient screening necessary?
Segel MC; Campbell WL; Medsger TA; Roumm AD
Gastroenterology; 1985 Sep; 89(3):485-8. PubMed ID: 3926590
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of screening a population with chronic gastroesophageal reflux.
Nietert PJ; Silverstein MD; Mokhashi MS; Kim CY; Glenn TF; Marsi VA; Hawes RH; Wallace MB
Gastrointest Endosc; 2003 Mar; 57(3):311-8. PubMed ID: 12612508
[TBL] [Abstract][Full Text] [Related]
3. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
Provenzale D; Schmitt C; Wong JB
Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
[TBL] [Abstract][Full Text] [Related]
4. Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer.
Streitz JM; Ellis FH; Tilden RL; Erickson RV
Am J Gastroenterol; 1998 Jun; 93(6):911-5. PubMed ID: 9647017
[TBL] [Abstract][Full Text] [Related]
5. Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma.
Katzka DA; Reynolds JC; Saul SH; Plotkin A; Lang CA; Ouyang A; Jimenez S; Cohen S
Am J Med; 1987 Jan; 82(1):46-52. PubMed ID: 3799692
[TBL] [Abstract][Full Text] [Related]
6. Screening and surveillance for complications related to gastroesophageal reflux disease.
Spechler SJ
Am J Med; 2001 Dec; 111 Suppl 8A():130S-136S. PubMed ID: 11749938
[TBL] [Abstract][Full Text] [Related]
7. The cost of surveillance for adenocarcinoma complicating Barrett's esophagus.
Achkar E; Carey W
Am J Gastroenterol; 1988 Mar; 83(3):291-4. PubMed ID: 3125739
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Barrett's esophagus in systemic sclerosis.
Wipff J; Allanore Y; Soussi F; Terris B; Abitbol V; Raymond J; Chaussade S; Kahan A
Arthritis Rheum; 2005 Sep; 52(9):2882-8. PubMed ID: 16142744
[TBL] [Abstract][Full Text] [Related]
9. Barrett's esophagus and risk of esophageal adenocarcinoma.
Cossentino MJ; Wong RK
Semin Gastrointest Dis; 2003 Jul; 14(3):128-35. PubMed ID: 14653412
[TBL] [Abstract][Full Text] [Related]
10. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis.
Gupta N; Bansal A; Wani SB; Gaddam S; Rastogi A; Sharma P
Gastrointest Endosc; 2011 Sep; 74(3):610-624.e2. PubMed ID: 21741639
[TBL] [Abstract][Full Text] [Related]
11. Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?
Inadomi JM; Saxena N
Dig Dis Sci; 2018 Aug; 63(8):2094-2104. PubMed ID: 29948571
[TBL] [Abstract][Full Text] [Related]
12. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Thrift AP
Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
[TBL] [Abstract][Full Text] [Related]
13. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis.
Choi SE; Perzan KE; Tramontano AC; Kong CY; Hur C
Cancer Prev Res (Phila); 2014 Mar; 7(3):341-50. PubMed ID: 24380852
[TBL] [Abstract][Full Text] [Related]
14. Endoscopic surveillance of Barrett's esophagus: another viewpoint.
Richter JE
Am J Gastroenterol; 1993 May; 88(5):630-2. PubMed ID: 8480722
[No Abstract] [Full Text] [Related]
15. Barrett's oesophagus: Current controversies.
Amadi C; Gatenby P
World J Gastroenterol; 2017 Jul; 23(28):5051-5067. PubMed ID: 28811703
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Cost-Effectiveness of Endoscopic Screening and Surveillance.
Saxena N; Inadomi JM
Gastrointest Endosc Clin N Am; 2017 Jul; 27(3):397-421. PubMed ID: 28577764
[TBL] [Abstract][Full Text] [Related]
17. The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis.
Omidvari AH; Hazelton WD; Lauren BN; Naber SK; Lee M; Ali A; Seguin C; Kong CY; Richmond E; Rubenstein JH; Luebeck GE; Inadomi JM; Hur C; Lansdorp-Vogelaar I
Gastroenterology; 2021 Aug; 161(2):487-494.e4. PubMed ID: 33974935
[TBL] [Abstract][Full Text] [Related]
18. The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
Anderson LA; Cantwell MM; Watson RG; Johnston BT; Murphy SJ; Ferguson HR; McGuigan J; Comber H; Reynolds JV; Murray LJ
Gastroenterology; 2009 Mar; 136(3):799-805. PubMed ID: 19162028
[TBL] [Abstract][Full Text] [Related]
19. Barrett's esophagus in scleroderma: increased prevalence and radiographic findings.
Recht MP; Levine MS; Katzka DA; Reynolds JC; Saul SH
Gastrointest Radiol; 1988; 13(1):1-5. PubMed ID: 3350262
[TBL] [Abstract][Full Text] [Related]
20. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study.
Bytzer P; Christensen PB; Damkier P; Vinding K; Seersholm N
Am J Gastroenterol; 1999 Jan; 94(1):86-91. PubMed ID: 9934736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
